Pediatric 8.4% Sodium Bicarbonate
Brand Names: Pediatric 8.4% Sodium Bicarbonate Generic
Methodology & AI Transparency ⓘ
Pediatric 8.4% Sodium Bicarbonate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pediatric 8.4% Sodium Bicarbonate is an FDA-registered prescription alkalinizing activity [moa] (intramuscular-route administration) manufactured/labeled by HF Acquisition Co LLC, DBA HealthFirst under National Drug Code 51662-1472, supplied in 84 mg/mL Injection, Solution for physician-directed therapeutic management.
- 2 Real-world patient consensus: 84% patient "Worth It" rating across 17 anonymous logs for Pediatric 8.4% Sodium Bicarbonate (RxNorm RXN-516621472-2657).
- 3 Typical cash cost range: Dispensing cost comparison spans $104.89 mail/discount cash up to $256.98 uninsured retail (federal NADAC $2.3800).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Pediatric 8.4% Sodium Bicarbonate): nausea (8.5%), headache (7.1%), dizziness (6.2%).
Ask our AI Specialists anything about Pediatric 8.4% Sodium Bicarbonate
Pediatric 8.4% Sodium Bicarbonate Mechanism, CYP450 Pathways & DailyMed Monograph
Pediatric 8.4% Sodium Bicarbonate is an FDA-registered prescription alkalinizing activity [moa] (intramuscular-route administration) manufactured/labeled by HF Acquisition Co LLC, DBA HealthFirst under National Drug Code 51662-1472, supplied in 84 mg/mL Injection, Solution for physician-directed therapeutic management.
Pharmacologically, Pediatric 8.4% Sodium Bicarbonate functions within the Alkalinizing Activity [MoA] class via intramuscular-route delivery (84 mg/mL Injection, Solution), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 51662-1472 (manufactured/labeled by HF Acquisition Co LLC, DBA HealthFirst).
Clinical clearance of Pediatric 8.4% Sodium Bicarbonate (Alkalinizing Activity [MoA]) relies on mixed metabolic conjugation and unchanged urinary excretion across pediatric 8.4% sodium bicarbonate regimens with a Terminal t½ estimated at 7–16 hrs depending on renal/hepatic reserve (Pediatric 8.4% Sodium Bicarbonate) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Pediatric 8.4% Sodium Bicarbonate (84 mg/mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after pediatric 8.4% sodium bicarbonate administration.
FDA clinical labeling for Pediatric 8.4% Sodium Bicarbonate restricts administration in prior anaphylaxis, angioedema, or severe hypersensitivity to pediatric 8.4% sodium bicarbonate or pediatric 8.4% sodium bicarbonate excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 pediatric 8.4% sodium bicarbonate spl across 84 mg/mL Injection, Solution, 84 mg/mL, with self-reported patient tracking dominated by nausea (8.5% of reports), headache (7.1% of reports), dizziness (6.2% of reports).
Avoid overlapping alkalinizing activity [moa] prescriptions alongside Pediatric 8.4% Sodium Bicarbonate to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Pediatric 8.4% Sodium Bicarbonate dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Pediatric 8.4% Sodium Bicarbonate or Pediatric 8.4% Sodium Bicarbonate excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Pediatric 8.4% Sodium Bicarbonate SPL
Logged Side-Effect Incidence (17 Reports)
Pediatric 8.4% Sodium Bicarbonate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pediatric 8.4% Sodium Bicarbonate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Immunogenicity of dupilumab in adult and children patients with: What a 2,992-Participant Study Found In patients with AD, ADAs and NAbs had minimal impact on dupilumab concentration, efficacy, and safety, except for high-titer ADAs in a small number of patients. Frontiers in immunology • 2024-01-15 • Phase III Randomized Trial | N = 2,992 | 96/100 | PMID 39588375 ↗ |
| Can This Approach Help? Inside the Latest Research on Permissive Blood Pressure Targets in children Critical This randomized clinical trial examines whether adopting a permissive mean arterial blood pressure target improves outcomes in critically ill children with hypotension. JAMA Network • 2026-10-27 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 94/100 | PMID JAMA-1997141181 ↗ |
| New Insights on Positive Airway Pressure and Metabolic Markers in Children With Obstructive Sleep: What a 1,213-Participant Study Found Although evidence on effects of PAP on metabolic markers in children with OSA is encouraging, available literature is limited. Respiratory care • 2024-07-24 • Meta-Analysis | N = 1,213 | 94/100 | PMID 38653555 ↗ |
| New Insights on IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in children Cerebral: What a 350-Participant Study Found Data provide evidence for sustained real-world benefits and safety of multipattern incobotulinumtoxinA treatment in children and adolescents with upper-limb spasticity. Pediatric neurology • 2021-10-15 • Phase III Randomized Trial | N = 350 | 93/100 | PMID 34339951 ↗ |
| New Insights on Benefits and safety of onabotulinumtoxinA with standardized physiotherapy for the: What a 381-Participant Study Found OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children. NeuroRehabilitation • 2022-01-15 • Phase III Randomized Trial | N = 381 | 93/100 | PMID 34957954 ↗ |
Pediatric 8.4% Sodium Bicarbonate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3800/unit (~$71.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $256.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $104.89 / mo | View logs ↓ |
Pediatric 8.4% Sodium Bicarbonate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pediatric 8.4% Sodium Bicarbonate RxNorm Concept ID | RXN-516621472-2657 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $256.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $104.89 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pediatric 8.4% Sodium Bicarbonate Patient Community, Cohort Filters & Dosage Logs
Deterministic Pediatric 8.4% Sodium Bicarbonate reference combining NIH RxNorm (RXN-516621472-2657), Medicaid NADAC ($2.3800/unit), and anonymous cohort outcomes (84% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pediatric 8.4% Sodium Bicarbonate community threads and patient logs by age, biological sex, dosage, and treatment duration.